125 related articles for article (PubMed ID: 3865777)
1. Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients.
Vrignaud P; Eghbali H; Hoerni B; Iliadis A; Robert J
Eur J Cancer Clin Oncol; 1985 Nov; 21(11):1307-13. PubMed ID: 3865777
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.
Robert J; Vrignaud P; Nguyen-Ngoc T; Iliadis A; Mauriac L; Hurteloup P
Cancer Treat Rep; 1985 Jun; 69(6):633-40. PubMed ID: 3893693
[TBL] [Abstract][Full Text] [Related]
3. Epirubicin. Clinical pharmacology and dose-effect relationship.
Robert J
Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
Mross K; Maessen P; van der Vijgh WJ; Gall H; Boven E; Pinedo HM
J Clin Oncol; 1988 Mar; 6(3):517-26. PubMed ID: 3162516
[TBL] [Abstract][Full Text] [Related]
5. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
Ramanathan-Girish S; Boroujerdi M
J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
[TBL] [Abstract][Full Text] [Related]
7. Sensitive and specific determination of the new anthracycline analog 4'-epidoxorubicin and its metabolites by high pressure liquid chromatography.
Deesen PE; Leyland-Jones B
Drug Metab Dispos; 1984; 12(1):9-13. PubMed ID: 6141919
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of 4'-modified analogs of doxorubicin. unique glucuronidation pathway for 4'-epidoxorubicin.
Weenen H; van Maanen JM; de Planque MM; McVie JG; Pinedo HM
Eur J Cancer Clin Oncol; 1984 Jul; 20(7):919-26. PubMed ID: 6589165
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of epirubicin.
Robert J
Clin Pharmacokinet; 1994 Jun; 26(6):428-38. PubMed ID: 8070217
[TBL] [Abstract][Full Text] [Related]
10. Effects of verapamil on the pharmacokinetics and metabolism of epirubicin.
Mross K; Hamm K; Hossfeld DK
Cancer Chemother Pharmacol; 1993; 31(5):369-75. PubMed ID: 8431970
[TBL] [Abstract][Full Text] [Related]
11. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults.
Avilés A; Arévila N; Díaz Maqueo JC; Gómez T; García R; Nambo MJ
Leuk Lymphoma; 1993 Oct; 11(3-4):275-9. PubMed ID: 8260898
[TBL] [Abstract][Full Text] [Related]
12. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.
Cersosimo RJ; Hong WK
J Clin Oncol; 1986 Mar; 4(3):425-39. PubMed ID: 3005521
[TBL] [Abstract][Full Text] [Related]
13. Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients.
Camaggi CM; Strocchi E; Martoni A; Angelelli B; Comparsi R; Pannuti F
Drugs Exp Clin Res; 1985; 11(4):285-94. PubMed ID: 3869807
[TBL] [Abstract][Full Text] [Related]
14. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
15. A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma.
Nair R; Ramakrishnan G; Nair NN; Saikia TK; Parikh PM; Joshi SR; Soman CS; Mukhadan M; Dinshaw KT; Advani SH
Cancer; 1998 Jun; 82(11):2282-8. PubMed ID: 9610711
[TBL] [Abstract][Full Text] [Related]
16. Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients.
Camaggi CM; Strocchi E; Comparsi R; Testoni F; Angelelli B; Pannuti F
Cancer Chemother Pharmacol; 1986; 18(1):47-50. PubMed ID: 3463434
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics of epirubicin in cancer patients].
Ohno T; Shimoyama T; Kimura K; Yamada H
Gan To Kagaku Ryoho; 1986 May; 13(5):1881-6. PubMed ID: 3458430
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma.
Robert J; Bui NB
Ann Oncol; 1992 Sep; 3(8):651-6. PubMed ID: 1450047
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart.
Salvatorelli E; Menna P; Lusini M; Covino E; Minotti G
J Pharmacol Exp Ther; 2009 Apr; 329(1):175-84. PubMed ID: 19144686
[TBL] [Abstract][Full Text] [Related]
20. Disposition of epirubicin and metabolites with repeated courses to cancer patients.
Morris RG; Kotasek D; Paltridge G
Eur J Clin Pharmacol; 1991; 40(5):481-7. PubMed ID: 1884722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
